. . "2018-05-14T00:00:00Z"^^ . "\u043A\u043B\u0456\u043D\u0456\u0447\u043D\u0435 \u0432\u0438\u043F\u0440\u043E\u0431\u0443\u0432\u0430\u043D\u043D\u044F"@uk . . . . . "CAMELLIA-TIMI"@en . . "2014-01-24T00:00:00Z"^^ . "klinisch onderzoek"@nl . . "A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or"@en . . "clinical trial"@en . "A Randomized, Double-blind, Placebo-controlled, Parallel-group Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or Multiple Cardiovascular Risk Factors"@en . . . . . . . . . . . . "ensayu cl\u00EDnicu"@ast . . . . . . . . . . . . . . . . . . . . . . . . . . . . "A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or"@en . . . . . . . . . . . . . . . . "40"^^ . . . "NCT02019264" . . . . . . "A Study to Evaluate the Effect of Long-term Treatment With BELVIQ (Lorcaserin HCl) on the Incidence of Major Adverse Cardiovascular Events and Conversion to Type 2 Diabetes Mellitus in Obese and Overweight Subjects With Cardiovascular Disease or"@en . . . . . . . . . . . . . . "12000"^^ . . . . . . . . . . . . . . . . . . . . . . . . . . .